JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) Beneish M-Score: -2.72 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:JSP JSP Pharmaceutical Manufacturing (Thailand) PCL BKK:JSP
80 GF Score
Price ฿1.78
GF Value ฿3.16
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is JSP Pharmaceutical Manufacturing (Thailand) PCL Beneish M-Score?

JSP Pharmaceutical Manufacturing (Thailand) PCL BKK:JSP 80 Beneish M-Score is -2.72 as of Jul. 16, 2026. GuruFocus rates BKK:JSP with a GF Score™ of 80/100 and a GF Value™ of ฿3.16 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,851 Consumer Packaged Goods companies, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks better than 67.21% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.72 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for JSP Pharmaceutical Manufacturing (Thailand) PCL's Beneish M-Score or its related term are showing as below:

BKK:JSP' s Beneish M-Score Range Over the Past 10 Years
Min: -2.86   Med: -2.44   Max: -0.44
Current: -2.72

During the past 7 years, the highest Beneish M-Score of JSP Pharmaceutical Manufacturing (Thailand) PCL was -0.44. The lowest was -2.86. And the median was -2.44.


JSP Pharmaceutical Manufacturing (Thailand) PCL Beneish M-Score Historical Data

* Premium members only.

The historical data trend for JSP Pharmaceutical Manufacturing (Thailand) PCL's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JSP Pharmaceutical Manufacturing (Thailand) PCL Beneish M-Score Chart

JSP Pharmaceutical Manufacturing (Thailand) PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 -0.44 -2.46 -2.62 -2.86

JSP Pharmaceutical Manufacturing (Thailand) PCL Quarterly Data
Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.55 -2.46 -2.44 -2.86 -2.72

BKK:JSP vs KHC, GIS: Beneish M-Score Comparison

For the Packaged Foods subindustry, JSP Pharmaceutical Manufacturing (Thailand) PCL's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JSP Pharmaceutical Manufacturing (Thailand) PCL Beneish M-Score vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, JSP Pharmaceutical Manufacturing (Thailand) PCL's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where JSP Pharmaceutical Manufacturing (Thailand) PCL's Beneish M-Score falls into.


BKK:JSP
80GF Score
JSP Pharmaceutical Manufacturing (Thailand) PCL BKK:JSP
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JSP Pharmaceutical Manufacturing (Thailand) PCL Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of JSP Pharmaceutical Manufacturing (Thailand) PCL for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9813+0.528 * 0.9841+0.404 * 0.5607+0.892 * 1.0973+0.115 * 1.1112
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1299+4.679 * -0.017086-0.327 * 1.1188
=-2.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ฿174.9 Mil.
Revenue was 201.296 + 257.8 + 261.332 + 263.365 = ฿983.8 Mil.
Gross Profit was 75.676 + 101.671 + 103.882 + 110.454 = ฿391.7 Mil.
Total Current Assets was ฿350.5 Mil.
Total Assets was ฿1,478.1 Mil.
Property, Plant and Equipment(Net PPE) was ฿1,060.4 Mil.
Depreciation, Depletion and Amortization(DDA) was ฿68.5 Mil.
Selling, General, & Admin. Expense(SGA) was ฿296.0 Mil.
Total Current Liabilities was ฿263.3 Mil.
Long-Term Debt & Capital Lease Obligation was ฿258.4 Mil.
Net Income was 0.453 + 18.086 + 14.163 + 28.128 = ฿60.8 Mil.
Non Operating Income was -5.346 + 6.404 + -1.508 + -2.6 = ฿-3.1 Mil.
Cash Flow from Operations was -9.89 + 57.482 + 23.271 + 18.272 = ฿89.1 Mil.
Total Receivables was ฿162.4 Mil.
Revenue was 227.728 + 240.729 + 228.67 + 199.425 = ฿896.6 Mil.
Gross Profit was 89.541 + 100.102 + 90.837 + 70.788 = ฿351.3 Mil.
Total Current Assets was ฿333.3 Mil.
Total Assets was ฿1,337.6 Mil.
Property, Plant and Equipment(Net PPE) was ฿895.9 Mil.
Depreciation, Depletion and Amortization(DDA) was ฿64.8 Mil.
Selling, General, & Admin. Expense(SGA) was ฿238.8 Mil.
Total Current Liabilities was ฿232.1 Mil.
Long-Term Debt & Capital Lease Obligation was ฿189.8 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(174.882 / 983.793) / (162.415 / 896.552)
=0.177763 / 0.181155
=0.9813

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(351.268 / 896.552) / (391.683 / 983.793)
=0.391799 / 0.398136
=0.9841

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (350.545 + 1060.428) / 1478.145) / (1 - (333.337 + 895.852) / 1337.595)
=0.045443 / 0.081045
=0.5607

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=983.793 / 896.552
=1.0973

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(64.794 / (64.794 + 895.852)) / (68.529 / (68.529 + 1060.428))
=0.067448 / 0.060701
=1.1112

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(296.02 / 983.793) / (238.763 / 896.552)
=0.300897 / 0.266312
=1.1299

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((258.363 + 263.314) / 1478.145) / ((189.833 + 232.123) / 1337.595)
=0.352927 / 0.315459
=1.1188

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(60.83 - -3.05 - 89.135) / 1478.145
=-0.017086

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

JSP Pharmaceutical Manufacturing (Thailand) PCL has a M-score of -2.72 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.72 mean?
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) has a Beneish M-Score of -2.72 as of Jul. 16, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. According to the industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #607 out of 1851 companies in the Consumer Packaged Goods industry, placing it in the top 32.8%.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL's Beneish M-Score too high?
JSP Pharmaceutical Manufacturing (Thailand) PCL's current Beneish M-Score is -2.72. Based on the distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #607 out of 1851 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, JSP Pharmaceutical Manufacturing (Thailand) PCL has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JSP Pharmaceutical Manufacturing (Thailand) PCL's Beneish M-Score compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #607 out of 1851 companies for Beneish M-Score. This puts JSP Pharmaceutical Manufacturing (Thailand) PCL in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Consumer Packaged Goods company?
A good Beneish M-Score depends on the Consumer Packaged Goods industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. JSP Pharmaceutical Manufacturing (Thailand) PCL's current Beneish M-Score is -2.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL stock overvalued right now?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿3.16, compared to a current price of ฿1.78 — trading 43.7% below its estimated fair value. The current Beneish M-Score is -2.72. JSP Pharmaceutical Manufacturing (Thailand) PCL's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP), the current Beneish M-Score is -2.72 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) Overvalued in 2026?

Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL stock appears to be undervalued. The current stock price of ฿1.78 is trading 43.7% below its estimated GF Value™ of ฿3.16. GuruFocus considers JSP Pharmaceutical Manufacturing (Thailand) PCL to be Significantly Undervalued.

Key valuation signals for BKK:JSP:

  • Beneish M-Score: -2.72
  • GF Value™: ฿3.16 vs. price of ฿1.78 (43.7% below fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the BKK:JSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


JSP Pharmaceutical Manufacturing (Thailand) PCL Business Description

Address No. 255, 257 Soi Sathupradit 58, Bang Pongphang, Yan Nawa, Bangkok, THA, 10120
JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing modern medicine, traditional medicine, herbal products, dietary supplements, medical supplies, and cleaning alcohol under the client's and the company's own trademarks. Maximum revenue for the company is generated from the sale of dietary supplements. The Group's reportable operating segments are: Manufacture and distribution of products under the company's brand name (Own brands), which generate maximum revenue, Manufacture and distribution of products under customers' brand name (OEM), Manufacture and distribution of hemodialysis solution and related medical supplies; and Service, research and development, and healthcare products training. Geographically, it operates principally in Thailand.
80GF Score

Get the complete analysis for BKK:JSP

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿1.78
Price
฿3.16
GF Value